Granted Patent
B2
US 12,747,300 · App. 17/875,295 · Granted Sep 29, 2026
Methods and antibody compositions for tumor treatment
Inventors:
Eric Smith (New York, NY); Samuel Davis (New York, NY); Bindu Varghese (Hopewell Junction, NY); Jessica R. Kirshner (New York, NY); Gavin Thurston (Briarcliff Manor, NY)
Assignee:
Regeneron Pharmaceuticals, Inc.
C07K16/2887C07K16/2803C07K16/2809A61K2039/505C07K2317/24C07K2317/31C07K2317/33C07K2317/51C07K2317/52C07K2317/522C07K2317/524C07K2317/526C07K2317/53C07K2317/56C07K2317/565C07K2317/66C07K2317/71C07K2317/73C07K2317/92
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The present invention provides bispecific antibodies that bind to CD3 and tumor antigens and methods of using the same. According to certain embodiments, the bispecific antibodies of the invention exhibit reduced effector functions and have a unique binding profile with regard to Fcγ receptors. The bispecific antibodies are engineered to efficiently induce T cell-mediated killing of tumor cells. According to certain embodiments, the present invention provides bispecific antigen-binding molecules comprising a first antigen-binding domain that specifically binds human CD3, a second antigen-binding molecule that specifically binds human CD20, and an Fc domain that binds Fcγ receptors with a specific binding pattern. In certain embodiments, the bispecific antigen-binding molecules of the present invention are capable of inhibiting the growth of B-cell or melanoma tumors expressing CD20. The bispecific antibodies of the invention are useful for the treatment of various cancers as well as other CD20-related diseases and disorders.
Claims (34)
1 . A method for treating a B-cell cancer in a subject, the method comprising: (a) selecting a subject who is afflicted with a cancer that is resistant to, or incompletely responsive to anti-CD20 monospecific therapy alone; and (b) administering to the subject a therapeutic amount of a bispecific antibody comprising a first antigen-binding domain that binds human CD3, a second antigen-binding domain that binds human CD20, and a heavy chain constant region tethered to each of the first and second antigen-binding domains, wherein:
(a) the first antigen-binding domain (A1) that binds human CD3 comprises three heavy chain complementarity determining regions (HCDR1, HCDR2, HCDR3) and three light chain complementarity determining regions (LCDR1, LCDR2, LCDR3), wherein
A1-HCDR1 comprises the amino acid sequence of SEQ ID NO: 12;
A1-HCDR2 comprises the amino acid sequence of SEQ ID NO: 14;
A1-HCDR3 comprises the amino acid sequence of SEQ ID NO: 16;
A1-LCDR1 comprises the amino acid sequence of SEQ ID NO: 20;
A1-LCDR2 comprises the amino acid sequence of SEQ ID NO: 22; and
A1-LCDR3 comprises the amino acid sequence of SEQ ID NO: 24;
(b) the second antigen-binding domain (A2) that binds human CD20 comprises three heavy chain complementarity determining regions (HCDR1, HCDR2, HCDR3) and three light chain complementarity determining regions (LCDR1, LCDR2, LCDR3), wherein
A2-HCDR1 comprises the amino acid sequence of SEQ ID NO: 4;
A2-HCDR2 comprises the amino acid sequence of SEQ ID NO: 6;
A2-HCDR3 comprises the amino acid sequence of SEQ ID NO: 8;
A2-LCDR 1 comprises the amino acid sequence of SEQ ID NO: 20;
A2-LCDR2 comprises the amino acid sequence of SEQ ID NO: 22; and
A2-LCDR3 comprises the amino acid sequence of SEQ ID NO: 24; and
(c) the heavy chain constant region comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 26, SEQ ID NO: 28, SEQ ID NO: 30 and SEQ ID NO: 32.
2 . The method of claim 1 , wherein the subject is selected on the basis of having a tumor that is resistant to, refractory to, or incompletely responsive to anti-CD20 monospecific therapy.
3 . The method of claim 1 , wherein the anti-CD20 monospecific therapy comprises or consists of an anti-CD20 monospecific antibody.
4 . The method of claim 3 , wherein the anti-CD20 monospecific antibody is rituximab.
5 . The method of claim 1 , wherein the B-cell cancer is lymphoma.
6 . The method of claim 5 , wherein the lymphoma is Non-Hodgkin's Lymphoma (NHL).
7 . The bispecific antibody of claim 1 , wherein the first antigen-binding domain comprises a heavy chain variable region (HCVR) amino acid sequence comprising SEQ ID NO: 10.
8 . The bispecific antibody of claim 1 , wherein the first antigen-binding domain comprises a light chain variable region (LCVR) amino acid sequence comprising SEQ ID NO: 18.
9 . The method of claim 1 , wherein the second antigen-binding domain comprises a heavy chain variable region (HCVR) amino acid sequence comprising SEQ ID NO: 2.
10 . The method of claim 1 , wherein the second antigen-binding domain comprises a light chain variable region (LCVR) amino acid sequence comprising SEQ ID NO: 18.
11 . The method of claim 1 , wherein the first antigen-binding domain that specifically binds human CD3 comprises a heavy chain variable region (HCVR) amino acid sequence comprising SEQ ID NO: 10, and a light chain variable region (LCVR) amino acid sequence comprising SEQ ID NO:18.
12 . The method of claim 1 , wherein the second antigen-binding domain that specifically binds human CD20 comprises a heavy chain variable region (HCVR) amino acid sequence comprising SEQ ID NO: 2, and a light chain variable region (LCVR) amino acid sequence comprising SEQ ID NO:18.
13 . The method of claim 1 , wherein the first antigen-binding domain comprises (i) a heavy chain variable region (HCVR) comprising the amino acid sequence of SEQ ID NO: 10, and (ii) a light chain variable region (LCVR) comprising the amino acid sequence of SEQ ID NO: 18; and wherein the second antigen-binding domain comprises (iii) a heavy chain variable region (HCVR) comprising the amino acid sequence of SEQ ID NO: 2, and a light chain variable region (LCVR) comprising the amino acid sequence of SEQ ID NO: 18.
14 . The method of claim 1 , wherein the bispecific antibody comprises a heavy chain constant region comprising the amino acid sequence of SEQ ID NO: 26.
15 . The method of claim 1 , wherein the bispecific antibody comprises a heavy chain constant region comprising the amino acid sequence of SEQ ID NO: 28.
16 . The method of claim 1 , wherein the bispecific antibody comprises a heavy chain constant region comprising the amino acid sequence of SEQ ID NO: 30.
17 . The method of claim 1 , wherein the bispecific antibody comprises a heavy chain constant region comprising the amino acid sequence of SEQ ID NO: 32.
18 . The method of claim 1 , wherein the bispecific antibody comprises a heavy chain constant region comprising the amino acid sequence of SEQ ID NO: 26 and a heavy chain constant region comprising the amino acid sequence of SEQ ID NO: 28.
19 . The method of claim 1 , wherein the bispecific antibody comprises a heavy chain constant region comprising the amino acid sequence of SEQ ID NO: 30 and a heavy chain constant region comprising the amino acid sequence of SEQ ID NO: 32.
Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Jun 6, 2024
From: SMITH, ERIC; DAVIS, SAMUEL; VARGHESE, BINDU; KIRSHNER, JESSICA R.; THURSTON, GAVIN
To: REGENERON PHARMACEUTICALS, INC.
Reel/Frame 067648/0072 →
Continuity (7)
Provisional Application
62033460
· Aug 5, 2014
Provisional Application
62007385
· Jun 3, 2014
Provisional Application
61981641
· Apr 18, 2014
Provisional Application
61955663
· Mar 19, 2014
References Cited (400)
US 5500362A
· Robinson et al.
· 1996
[cited by applicant]
US 5624821A
· Winter et al.
· 1997
[cited by applicant]
US 5648260A
· Winter et al.
· 1997
[cited by applicant]
US 5658570A
· Newman et al.
· 1997
[cited by applicant]
US 5677180A
· Robinson et al.
· 1997
[cited by applicant]
US 5721108A
· Robinson et al.
· 1998
[cited by applicant]
US 5736137A
· Anderson et al.
· 1998
[cited by applicant]
US 5776456A
· Anderson et al.
· 1998
[cited by applicant]
US 5843439A
· Anderson et al.
· 1998
[cited by applicant]
US 6120767A
· Robinson et al.
· 2000
[cited by applicant]
US 6180377B1
· Morgan et al.
· 2001
[cited by applicant]
US 6224866B1
· Barbera-Guillem
· 2001
[cited by applicant]
US 6399061B1
· Anderson et al.
· 2002
[cited by applicant]
US 6455043B1
· Grillo-Lopez
· 2002
[cited by applicant]
US 6528624B1
· Idusogie et al.
· 2003
[cited by applicant]
US 6551592B2
· Lindhofer et al.
· 2003
[cited by applicant]
US 6652852B1
· Robinson et al.
· 2003
[cited by applicant]
US 6682734B1
· Anderson et al.
· 2004
[cited by applicant]
US 6893625B1
· Robinson et al.
· 2005
[cited by applicant]
US 7151164B2
· Hansen et al.
· 2006
[cited by applicant]
US 7214775B2
· Hanai et al.
· 2007
[cited by applicant]
US 7396917B2
· Bowdish et al.
· 2008
[cited by applicant]
US 7563441B2
· Graus et al.
· 2009
[cited by applicant]
US 7597889B1
· Armour et al.
· 2009
[cited by applicant]
US 7608260B2
· Schenerman et al.
· 2009
[cited by applicant]
US 7700097B2
· Braskawshy et al.
· 2010
[cited by applicant]
US 7700099B2
· Strohl
· 2010
[cited by applicant]
US 7728114B2
· Mach et al.
· 2010
[cited by applicant]
US 7820166B2
· Lanzavecchia et al.
· 2010
[cited by applicant]
US 7824684B2
· Graus et al.
· 2010
[cited by applicant]
US 7867491B2
· Yang et al.
· 2011
[cited by applicant]
US 7879984B2
· Martin et al.
· 2011
[cited by applicant]
US 7960512B2
· Stavenhagen et al.
· 2011
[cited by applicant]
US 8075884B2
· Bowdish et al.
· 2011
[cited by applicant]
US 8076459B2
· Hofmeister et al.
· 2011
[cited by applicant]
US 8084026B2
· Glaser et al.
· 2011
[cited by applicant]
US 8097713B2
· Martin et al.
· 2012
[cited by applicant]
US 8153583B2
· Carton et al.
· 2012
[cited by applicant]
US 8236314B2
· Kai et al.
· 2012
[cited by applicant]
US 8268972B2
· Whitfeld et al.
· 2012
[cited by applicant]
US 8329181B2
· Martin et al.
· 2012
[cited by applicant]
US 8383109B2
· Lazar et al.
· 2013
[cited by applicant]
US 8409568B2
· Gao et al.
· 2013
[cited by applicant]
US 8597648B2
· Guo
· 2013
[cited by examiner]
US 8961967B2
· Strohl et al.
· 2015
[cited by applicant]
US 9359437B2
· Davis et al.
· 2016
[cited by applicant]
US 9657102B2
· Smith et al.
· 2017
[cited by applicant]
US 20030026804A1
· Grillo-Lopez
· 2003
[cited by applicant]
US 20040093621A1
· Shitara et al.
· 2004
[cited by applicant]
US 20050025764A1
· Watkins et al.
· 2005
[cited by applicant]
US 20050053602A1
· Brunetta
· 2005
[cited by applicant]
US 20050191297A1
· Brunetta
· 2005
[cited by applicant]
US 20050271658A1
· Brunetta et al.
· 2005
[cited by applicant]
US 20060024295A1
· Brunetta
· 2006
[cited by applicant]
US 20060110387A1
· Brunetta
· 2006
[cited by applicant]
US 20060233797A1
· Gujrathi
· 2006
[cited by applicant]
US 20060240007A1
· Sanders
· 2006
[cited by applicant]
US 20060263355A1
· Quan et al.
· 2006
[cited by applicant]
US 20070009523A1
· Presta
· 2007
[cited by applicant]
US 20070014720A1
· Gazit-Bornstein et al.
· 2007
[cited by applicant]
US 20070041972A1
· Rother et al.
· 2007
[cited by applicant]
US 20090252729A1
· Farrington et al.
· 2009
[cited by applicant]
US 20100183615A1
· Kufer et al.
· 2010
[cited by applicant]
US 20100267934A1
· Winkel et al.
· 2010
[cited by applicant]
US 20100325744A1
· Schuurman et al.
· 2010
[cited by applicant]
US 20110077383A1
· Dall'Acqua et al.
· 2011
[cited by applicant]
US 20110245473A1
· Igawa et al.
· 2011
[cited by applicant]
US 20120071634A1
· Igawa et al.
· 2012
[cited by applicant]
US 20120100140A1
· Reyes et al.
· 2012
[cited by applicant]
US 20120189643A1
· Carton et al.
· 2012
[cited by applicant]
US 20120237515A1
· Bell et al.
· 2012
[cited by applicant]
US 20130108623A1
· D'Angelo et al.
· 2013
[cited by applicant]
US 20130129723A1
· Blankenship et al.
· 2013
[cited by applicant]
US 20170008951A1
· Block et al.
· 2017
[cited by applicant]
US 20180303953A1
· Van Berkel et al.
· 2018
[cited by applicant]
US 20240368312A1
· Haber et al.
· 2024
[cited by applicant]
EP 0237378B1
· 1996
[cited by applicant]
EP 1400534A1
· 2004
[cited by applicant]
EP 1176981B1
· 2005
[cited by applicant]
EP 1185299B1
· 2007
[cited by applicant]
EP 2447372A2
· 2012
[cited by applicant]
EP 2500353A2
· 2012
[cited by applicant]
EP 2918604A1
· 2015
[cited by applicant]
EP 3252078A1
· 2017
[cited by applicant]
WO 1997028267A1
· 1997
[cited by applicant]
WO 1999043713A1
· 1999
[cited by applicant]
WO 1999058572A1
· 1999
[cited by applicant]
WO 2000042072A2
· 2000
[cited by applicant]
WO 2003026490A2
· 2003
[cited by applicant]
WO 2004106380A2
· 2004
[cited by applicant]
WO 2004106383A1
· 2004
[cited by applicant]
WO 2005000901A2
· 2005
[cited by applicant]
WO 2005040220A1
· 2005
[cited by applicant]
WO 2005118635A3
· 2005
[cited by applicant]
WO 2005130458A2
· 2006
[cited by applicant]
WO 2007024715A2
· 2007
[cited by applicant]
WO 2007042261A2
· 2007
[cited by applicant]
WO 2007093630A1
· 2007
[cited by applicant]
WO 2008076379A3
· 2008
[cited by applicant]
WO 2008119567A2
· 2008
[cited by applicant]
WO 2008147143A2
· 2008
[cited by applicant]
WO 2009018411A1
· 2009
[cited by applicant]
WO 2009023540A1
· 2009
[cited by applicant]
WO 2009030368A1
· 2009
[cited by applicant]
WO 2009106096A1
· 2009
[cited by applicant]
WO 2010054212A1
· 2010
[cited by applicant]
WO 2010063785A2
· 2010
[cited by applicant]
WO 2010085682A2
· 2010
[cited by applicant]
WO 2010151792A1
· 2010
[cited by applicant]
WO 2011090762A1
· 2011
[cited by applicant]
WO 2011137362A1
· 2011
[cited by applicant]
WO 11163566A1
· 2011
[cited by applicant]
WO 2012022982A2
· 2012
[cited by applicant]
WO 2012035141A1
· 2012
[cited by applicant]
WO 2012073985A1
· 2012
[cited by applicant]
WO 2012087746A1
· 2012
[cited by applicant]
WO 2012109285A2
· 2012
[cited by applicant]
WO WO2012143524A2
· 2012
[cited by examiner]
WO 2012162067A2
· 2012
[cited by applicant]
WO 2013012733A1
· 2013
[cited by applicant]
WO 2013026839A1
· 2013
[cited by applicant]
WO 2013072406A1
· 2013
[cited by applicant]
WO 2013072415A1
· 2013
[cited by applicant]
WO 2013112986A1
· 2013
[cited by applicant]
WO 2013157105A1
· 2013
[cited by applicant]
WO 2013163427A
· 2013
[cited by applicant]
WO 2013184761A1
· 2013
[cited by applicant]
WO 2014012085A2
· 2014
[cited by applicant]
WO 2014022540A1
· 2014
[cited by applicant]
WO 2014047231A1
· 2014
[cited by applicant]
WO 2014051433A1
· 2014
[cited by applicant]
WO 2014056783A1
· 2014
[cited by applicant]
WO 2014121087A1
· 2014
[cited by applicant]
WO 2015006749A2
· 2015
[cited by applicant]
WO 2015091738A1
· 2015
[cited by applicant]
WO 2015143079A1
· 2015
[cited by applicant]
WO 2016081490A1
· 2016
[cited by applicant]
WO 2016161010A2
· 2016
[cited by applicant]
WO 2017053856A1
· 2017
[cited by applicant]
WO 2017112762A1
· 2017
[cited by applicant]
WO 2018093821A1
· 2018
[cited by applicant]
WO 2021021469A1
· 2021
[cited by applicant]
Chao et al. (Cancer Management and Research 2013:5 251-269). (Year: 2013).
[cited by examiner]
Wong et al. (Haematologica. Dec. 2013;98(12):1930-1938, supplemental pages included, document has been renumbered as pp. 1-27). (Year: 2013).
[cited by examiner]
P01834 (GenPept, Ig kappa chain C region, pp. 1-4, Feb. 19, 2014). (Year: 2014).
[cited by examiner]
“IgG-Fc Engineering for Therapeutic Use,” InvivoGen Insight, 1 page, (2006). [Author Unknown] [Retrieved from the Internet Apr. 4, 2014: < URL: http://www.invivogen.comiclocs/Insight200605 pdf>].
[cited by applicant]
“IgG-Fe engineering for therapeutic use,” Invivogen, 2 pages, (2007). [Author Unknown] [Retrieved from the Internet Jan. 12, 2011: <URL: http://www.invivogen.com/ressource.php?ID=22>].
[cited by applicant]
Aalberse et al., “IgG4 breaking the rules,” Immunology, 105(1):9-19, (2002).
[cited by applicant]
Advani et al., “New immune strategies for the treatment of acute pymphoblastic leukemia: antiobodies and chimeric antigen receptors,” Hematology, vol. 2013 (No. 1): (Dec. 1, 2013).
[cited by applicant]
Aklilu et al., “Depletion of normal B cells with rituximab as an adjunct to IL-2 therapy for renal cell carcinoma and melanoma,” Annals of Oncology 15: 1109-1114; Chicago, IL (2004).
[cited by applicant]
Alegre et al., “Effect of a Single Amino Acid Mutation on the Activating and Immunosuppressive Properties of a Humanized OKT3 Monoclonal Antibody”, J Immunol, 148(11):3461-3468, ISSN: 0022-1767, (1992).
[cited by applicant]
Almagro et al., “Humanization of antibodies,” Front Biosci, vol. 13, pp. 1619-163, (2008).
[cited by applicant]
An et al., “IgG2m4, an engineered antibody isotype with reduced Fc function,” Landes Bioscience, 1(6):572-579, (2009).
[cited by applicant]
Anonymous, “Clinical Trails Register: A Phase I Study to Assess Safety and Tolerability of REGN1979, an anti-CD20 x anti-CD3 bispecific monoclonal antibody, and REGN2810, and anti-programmed death-1 (PD-1) monoclonal an…
[cited by applicant]
Anonymous, “Study of REGN2810 and REGN1979 in Patients with Lymphoma or Acute Lymphoblastic Leukemia.” [Retrieved from the Internet Mar. 15, 2017: <URL: https://www.api.liveclinicaltrials.com/trialpage?dcn=10963&city=Ba…
[cited by applicant]
Armour et al., “Differential binding to human FcyRIIa and FcyRIIb receptors by human IgG wildtype and mutant antibodies,” Molecular Immunology, 40:585-593, (2003).
[cited by applicant]
Armour et al., “Recombinant human IgG molecules lacking Fcy receptor I binding and monocyte triggering activities”, J. Immunol., 29: 2613-2624, (1999).
[cited by applicant]
Bae et al., “Identification of the amino acid residues involved in human IgG transport into egg yolk of Japanese quail,” Molucular Immunology, vol. 47:1404-1410, (2010).
[cited by applicant]
Baeuerle et al., “Bispecific T-cell engaging antibodies for cancer therapy,” Cancer Res, 69(12):4941-4944, doi: 10.1158/0008-5472.CAN-09-0547, (2009).
[cited by applicant]
Bannerji et al., “Phase 1 Study of REGN1979, an Anti-CD20 x Anti-CD3 Bispecific Monoclonal Antibody, in Patients with CD20+ B-Cell Malignancies Previously Treated with CD20-Directed Antibody Therapy,” Blood, vol. 128 (2…
[cited by applicant]
Bargou et al., “Tumor egression in Cancer Patients by Very Low Doses of a T Cell-Engaging Antibody,” Science Magazine, vol. 321: 974-977, (2008).
[cited by applicant]
Becker et al., “Evaluation of a combinatorial cell engineering approach to overcome apoptotic effects in XBP-1(s) expressing cells,” Journal of Biotechnology, vol. 164:198-206, (2010).
[cited by applicant]
Blincyto (blinatumomab) for injection, for intravenous use Initial U.S. Approval: 2014, “Highlights of Prescribing Information,” gackage insert.
[cited by applicant]
Bloom et al., “Intrachain disulfide bond in the core hinge region of human IgG4,” Protein Science, 6:407-415, (1997).
[cited by applicant]
Boehrer et al., “Cytotoxic effects of the trifunctional bispecific antibody FBTACI5 in ex-vivo cells of chronic lymphocytic leukemia depend on immune-mediated mechanisms,” Anti-Cancer Drugs, 22:519-530, (2011).
[cited by applicant]
Bortoletto et al., “Optimizing anti-CD3 affinity for effective T cell targeting against tumor cells,” Eur. J. Immunol., vol. 32:3102-3107, (2002).
[cited by applicant]
Brekke et al., “The structural requirements for complement activation by IgG: does it hinge on the hinge?” Today, 16(2):85-90, (1995).
[cited by applicant]
Brownstein et al., “First-in-human study assessing safety and tolerability of REGN1979, a novel CD20xCD3 bispecific antibody, in patients with CD20+ B-cell malignancies previously treated with anti-CD20 therapy,” Americ…
[cited by applicant]
Buhmann et al., “Immunotherapy of recurrent B-cell malignancies after allo-SCT with Bi20 (FBTA05), a trifunctional anti-CD3 x anti-CD20 antibody and donor lymphocyte infusion,” Bone Marrow Transplantation, 43:383-397, (…
[cited by applicant]
Buhmann et al., “Immunotherapy with FBTA05 (Bi20), a trifunctional bispecific anti-CD3 x anti-CD20 antibody and donor lymphocyte infusion (DLI) in relapsed or refractory B-cell lymphoma after allogeneic stem cell transp…
[cited by applicant]
Canfield et al., “The Binding Affinity of Human Igg for Its High Affinity FC Receptor is Determined by Multiple Amino Acids in the Ch2 Domain and is Modulated by the Hinge Region,” J. Exp. Med., 173(6):1483-1491, (1991).
[cited by applicant]
Cao et al., “Multiformat T-Cell-Engaging Bispecific Antibodies Targeting Human Breast Cancers,” Angew Chem Int Ed Engl, 54(24):7022-7027, doi: 10.1002/anie.201500799, (2015).
[cited by applicant]
Carter, “Potent Antibody Therapeutics by Design,” Journal of Immunology, Nature Pub. Group, 6:343-357, (2006).
[cited by applicant]
Chan et al., “Therapeutic antibodies for autoimmunity and inflammation,” Macmillan Publishers Limited (Nature Reviews, Immunology), vol. (10):301-316, (2010).
[cited by applicant]
Chappel et al., “Identification of a Secondary FcyRI Binding Site within a Genetically Engineered Human IgG,” Journal of Biological Chemistry, 268(33): 25124-25131, (1993).
[cited by applicant]
Chappel et al., “Identification of the FC-Gamma Receptor Class I Binding Site in Human Igg Through the Use of Recombinant Igg1-Igg2 Hybrid and Point-Mutated Antibodies,” Proc. Natl. Acad. Sci. USA, 88(20):9036-9040, (19…
[cited by applicant]
Chatenoud et al., “CD3-specific antibodies: a portal to the treatment of autoimmunity,” Nature, vol. (7): 622-632, (Aug. 2007). [doi:10.1038/nri2134: <URL: www.nature.com/reviews/immunol>].
[cited by applicant]
Chen et al., “Strategies for Generating Diverse Antibody Reportoires Using Transgenic Animals Expressing Human Antibodies,” Front. Immunol. vol. 9, Article 460; Mar. 2018; 7 pages. doi: 10.3389/fimmu.2018.00460.
[cited by applicant]
Clark, “IgG Effector Mechanisms,” Chem Immunol. Basel, Karger, 65:88-110, (1997).
[cited by applicant]
Conrad et al., “TCR and CD3 Antibody Cross-Reactivity in 44 Species,” Cytometry Part A, 71A:925-933, (2007).
[cited by applicant]
Dall'Acqua et al., “Modulation of the Effector Functions of a Human IgG1 through Engineering of Its Hinge Region,” Journal of Immunology, 177:1129-1138, (2006).
[cited by applicant]
Damschroder et al., “Analysis of human and primate CD2 molecules by protein sequence and epitope mapping with anti-human CD2 antibodies,” Molecular Immunology, vol. 41:985-1000, (2004).
[cited by applicant]
Dangl et al., “Segmental flexibility and complement fixation of genetically engineered chimeric human, rabbit and mouse antibodies,” The EMBO Journal, 7(7):1989-1994, (1988).
[cited by applicant]
Duncan et al., “Localization of the binding site for the human high-affinity Fc receptor on IgG”, Nature, 332:563-564, (1988).
[cited by applicant]
Fossati et al., “Immunological changes in the ascites of cancer patients after intraperitoneal administration of the bispecific antibody catumaxomab (anti-EpCAManti-CD3),” Gynecol Oncol, 138(2):343-351, doi: 10.1016/J.Y…
[cited by applicant]
Gall et al., “T cells armed with anti-CD3 x anti-CD20 bispecific antibody enhance killing of CD20+ malignant B cells and bypass complement-mediated rituximab resistance in vitro”, Experimental Hematology, 33(4):452-459,…
[cited by applicant]
Gergely et al., “The two binding-site models of human IgG binding Fcy receptors”, The FASEB Journal, 4:3275-3283, (1990).
[cited by applicant]
Greenwood et al., “Structural Motifs Involved In Human IGG Antibody Effector Functions,” Eur. J. Immunology, 23(5):1098-1104, (1993).
[cited by applicant]
Grubb, “Human Immunoglobulin Allotypes and Mendelian Polymorphisms of the Human Immunoglobulin Genes,” in Oss CJ, Regenmortel MHV (eds); Immunochemistry, New York, Dekker (1994); pp. 47-68.
[cited by applicant]
Harlow et al., Antibodies, A Laboratory Manual, Cold Spring Harbor Laboratory; (1998) pp. 37-47.
[cited by applicant]
Haso et al., “Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymophoblastic leukemia,” Blood, vol. 121 (No. 7):1165-1174, (2013).
[cited by applicant]
Hezareh et al., “Effector function activities of a panel of mutants of a broadly neutralizing antibody against human immunodeficiency virus type 1,” J Virol, 75(24):12161-12168, doi: 10.1128/JVI.75.24.12161-12168.2001, …
[cited by applicant]
Jacobsen et al., “Molecular and Functional Characterization of Cynomolgus Monkey IgG Subclasses,” Journal Immunology, 186:341-349, (2011).
[cited by applicant]
Jefferis et al., “Interaction sites on human IgG-Fc for FcyR: current models”, Immunology Letters, 82:57-65, (2002).
[cited by applicant]
Jefferis et al., “Recognition sites on human IgG for Fcy receptors: the role of glycosylation,” Immunology Letters, 44:111-117, (1995).
[cited by applicant]
Jung et al., “Target Cell-Induced T Cell Activation with Bi- and Trispecific Antibody Fragments”, Eur J Immunol, vol. 21, pp. 2431-2435, doi: 10.1002/EJI.1830211020, (1991).
[cited by applicant]
Kapur et al., “IgG-effector functions: The Good, The Bad and The Ugly,” El Sevier, vol. 160:139-144, (2014).
[cited by applicant]
Kazutomo, Biochemical Encyclopedia, 1998, 3rd Edition, pp. 265 to 266.
[cited by applicant]
Klein et al., “Progress in overcoming the chain association issue in bispecific heterodimeric IgG antibodies,” mAbs, Landes Bioscience, 4(6):1-11, (2012).
[cited by applicant]
Klinger et al., “Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomab,” Blood, 119:6226-6233, (201…
[cited by applicant]
Köhnke et al., “Increase of PD-L1 expressing B-precursor ALL cells in a patient resistant to the CD19/CD3-bispecific T cell engager antibody blinatumomab,” Journal of Hematoloty & Oncology, vol. 8 (No. 111):5 pages, (20…
[cited by applicant]
Kontermann, “Dual targeting strategies with bispecific antibodies,” mAbs, Landes Bioscience, 4(2):182-197, (2012).
[cited by applicant]
Kumar et al., “Expression of CD20 in B Cell Precursor Acute Lymphoblastic Leukemia,” Indian J. Hematol Blood Transfus, vol. 30 (No. 1):16-18, (2014).
[cited by applicant]
Kung et al., “Monoclonal Antibodies Defining Distinctive Human T Cell Surface Antigens,” Science, 206:347-349, (1979).
[cited by applicant]
Labrijn et al., “When binding is enough: nonactivating antibody formats”, Current Opinion in Immunology, 20:479-485, (2008).
[cited by applicant]
Lau et al., “Chimeric Anti-CD14 IGG2/4 Hybrid Antibodies for Therapeutic Intervention in Pig and Human Models of Inflammation,” J Immunol, 191:4769-4777, doi: 10.4049/jimmunol.1301653, (2013).
[cited by applicant]
Le Tourneau et al., “Dose Escalation Methods in Phase I Cancer Clinical Trials,” National Cancer Institute, vol. 101 (Issue 10): 708-720, (2009).
[cited by applicant]
Leonard et al., “Targeted Treatment and New Agents in Diffuse Large B-Cell Lymphoma,” Semin Hematol, 45(suppl 2):S11-S16, (2008).
[cited by applicant]
Li et al., “A Novel Bispecific Antibody, S-Fab, Induces Potent Cancer Cell Killing,” J Immunother, 38(9):350-356, doi: 10.1097/CJI.0000000000000099, (2015).
[cited by applicant]
Liu et al., “Improvement in soluble expression levels of a diabody by exchanging expression vectors”, Protein Expression and Purification, 62:15-20, (2008).
[cited by applicant]
Lum et al., “CD2O-Targeted T Cells after Stem Cell Transplantation for High Risk and Refractory Non-Hodgkin's Lymphoma,” Pbiol Blood Marrow Transplant, 19(6):925-933, (2013).
[cited by applicant]
Lum et al., “Multiple infusions of CD20-targeted T cells and low-dose IL-2 after SCT for high-risk non-Hodgkin's lymphoma: A pilot study,” Bone Marrow Transplantation, 49:73-79, (2004). [Puplished online Sep. 23, 2013].
[cited by applicant]
Lund et al., “Human FcyRI and FcyRII Interact with Distinct but Overlapping Sites on Human IgG”, Journal of Immunology, 147(8):2657-2662, (1991).
[cited by applicant]
Maude et al., “Managing Cytokine Release Syndrome Associated With Novel T Cell-Engaging Therapies,” Cancer Journal, vol. 20(2): 119-122, (2014).
[cited by applicant]
Michaelsen et al., “Antibody Dependent Cell-Mediated Cytotoxicity Induced by Chimeric Mouse-Human IgG Subclasses and IgG3 Antibodies with Altered Hinge Region,” Molecular Immunology, 29(3):319-326, (1992).
[cited by applicant]
Morgan et al., “The N-terminal end of the CH2 domain of chimeric human IgG1 anti-HLA-DR is necessary for Gig, FcyRI and FcyRII binding,” Immunology, 86:319-324, (1995).
[cited by applicant]
Mueller et al., “Humanized Porcine VCAM-Specific Monoclonal Antibodies with Chimeric IgG2/G4 Constant Regions Block Human Leukocyte Binding to Porcine Endothelial Cells,” Molecular Immunology, 34(6): 441-452, (1997).
[cited by applicant]
Nagorsen et al., “Blinatumomab: A historical perspective,” Pharmacology & Therapeutics, 136:334-342 (2012).
[cited by applicant]
Natsume et al., “Engineered Antibodies of IgG1IIgG3 Mixed Isotype with Enhanced Cytotoxic Activities,” Cancer Research, 68:(10):3863-3872, (2008).
[cited by applicant]
NCBI MedGen 44126 definition for “Pre-B Acute Lymphoblastic Leukemia” retrieved from the Internet on Dec. 11, 2018; pp. 1-4, available at <https://www.ncbi.nlm.nih.gov/medgen/44126> (2018).
[cited by applicant]
Oganesyan et al., “Structural characterization of a human Fc fragment engineered for lack of effector functions,” Acta Crystallographica Section D Biological Crystallography, D64:700-704, (2008).
[cited by applicant]
Ontology Lookup Serviec, EFO 0000220, “acute lumphoblastic leukemia” retrieved from the Internet on Dec. 11, 2018, pp. 1-6; available at <http://www.ebi.ac.uk/ols/ontologies/efo/terms?short_form=EFO_0000220> (2018).
[cited by applicant]
Patel et al., “IGG subclass variation of a monoclonal antibody binding to human Fc-gamma receptors”, American Journal of Biochemistry and Biotechnology, 9(3):206-218, (2013).
[cited by applicant]
Pessano et al., “The T3/T cell receptor complex: antigenic distinction between the two 20-kd T3 (T3-δ and T3-€) subunits,” The EMBO Journal, 4(2):337-344, (1985).
[cited by applicant]
Peters et al., “Engineering an Improved IgG4 Molecule with Reduced Disulfide Bond Heterogeneity and Increased Fab Domain Thermal Stability,” Journal of Biological Chemistry, 287(29): 24525-24533, (2012).
[cited by applicant]
Press Release: U.S. FDA Approves Darzelex® (daratumumab) Split-Dosing Regimen, Feb. 12, 2019. (www.janssen.com).
[cited by applicant]
Reddy et al., “Elimination of Fc Receptor-Dependent Effector Functions of a Modified IgG4 Monoclonal Antibody to Human CD4,” Journal of Immunology, 164:1925-1933, (2000).
[cited by applicant]
Removab 10 microgram concentrate for solution for infusion packaeg; Annex 1; Summay of Product Characteristics, 1-44, package insert.
[cited by applicant]
Richards et al., “Optimization of antibody binding to FcyRIIa enhances macrophage phagocytosis of tumor cells,” Molecular Cancer Therapeutics (Xencor, Inc.), vol. (8):2517-2527, (2008). [Retrieved from the Internet Sep.…
[cited by applicant]
Rother et al., : “Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuna,” Nature Biotechnology, 25(11):1256-1264, (2007).
[cited by applicant]
Roux et al., “Comparisons of the ability of human IgG3 hinge mutants, IgM, IgE and IgA2, to form small immune complexes: Arole for flexibility and geometry,” The Journal of Immunology, 161:4083- 4090, (1998).
[cited by applicant]
Roux et al., “Flexibility of Human IgG Subclasses,” Journal of Immunology, 159:3372-3382, (1997).
[cited by applicant]
Ruf et al., “Induction of a long-lasting antitumor immunity by a trifunctional bispecific antibody,” Blood Journal, vol. 98, No. 9: 2526-2534, (2001).
[cited by applicant]
Salfeld, “Isotype selection in antibody engineering,” Nature Biotechnology, 25(12):1369-1372, (2007).
[cited by applicant]
Sarmay et al., “Mapping and Comparison of the Interaction Sites on the Fc Region of IgG Responsible for Triggering Antibody Dependent Cellular Cytotoxicity (ADCC) through Different Types of Human Fcy Receptor,” Molecula…
[cited by applicant]
Sathish et al., “Challenges and approaches for the development of safer immunomodulatory biologics,” Nature Reviews Drug Discovery, 12:306-324, (2013).
[cited by applicant]
Schaefer et al., “Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodies,” PNAS, 108(27):11187-11192, doi: 10.1073/pnas.1019002108, (2011).
[cited by applicant]
Schuster et al., “Immunotherapy with the trifunctional anti-CD20 x anti-CD3 antibody FBTA05 Lymphomun) in paediatric high-risk patients with recurrent CD20-positive B cell malignancies,” British Journal of Haematolgy, v…
[cited by applicant]
Scott et al., “Antibody Therapy of Cancer,” Nature, vol. 12:278-287, (Apr. 2012).
[cited by applicant]
Segal et al., “Bispecific antibodies in cancer therapy,” Current Opinion in Immunology, 11:558-562, (1999).
[cited by applicant]
Sensel et al., “Amino Acid Differences in the N-Terminus of CH2 Influence the Relative Abilities of IgG2 and IgG3 to Activate Complement”, Molecular Immunology, 34(14):1019-1029, (1997).
[cited by applicant]
Shields et al., High resolution mapping of the binding site on human IgG1 for FcgammaRI, FcganmaRII, FcgammaRIII, and FcRn and design of IgG1 variants with improved binding to the FcgammaR, J Biol Chem, 276(9):6591-6604…
[cited by applicant]
Siberil et al., “Molecular aspects of human FcyR interactions with IgG: Functional and therapeutic consequences,” Immunology Letters, 106:111-118, (2006).
[cited by applicant]
Siiman et al., “Cell Surface Receptor-Antibody Association Constants and Enumeration of Receptor Sites for Monoclonal Antibodies,” Cytometry, 40:316-326, (2000).
[cited by applicant]
Smith et al., “A novel, native-format bispecific antibody triggering T-cell killing of B-cell is robustly active in mouse tumor models and cynomolgus monkeys,” Scientific Reports, vol. 5(No. 11):(Dec. 11, 2015); p. 1794…
[cited by applicant]
Stanglmaier et al., “Bi20 (FBTA05), a novel trifunctional bispecific antibody (anti-CD20 x anti-CD3), mediates efficient killing of B-cell lymphoma cells even with very low CD20 expression levels”, Int. J. Cancer, 123(5…
[cited by applicant]
Stel et al., “The role of B cell-mediated T cell costimulation in the efficacy of the T cell retargeting bispecific antibody BIS20x3,” J Immunol, 173(10):6009-6016, (2004).
[cited by applicant]
Stevenson, “Chemical Engineering at the Antibody Hinge,” Chem Immunol. Basel, Karger, 65:57-72, (1997).
[cited by applicant]
Strop et al., “Generating Bispecific Human IgG1 and IgG2 Antibodies from Any Antibody Pair”, J. Mol. Biol., 420(3):204-219, (2012).
[cited by applicant]
Stubenrauch et al., “Impact of Molecular Processing in the Hinge Region of Therapeutic IgG4 Antibodies on Disposition Profiles in Cynomolgus Monkeys,” Drug Metabolism and Disposition, vol. 38(No. 1):84-91, (2010).
[cited by applicant]
Sun et al., “Anti-CD20/CD3 T cell-dependent bispecific antibody for the treatment of B cell malignancies,” Science Translational Medicine, 7(287):287ra70, 10 pages, (2015).
[cited by applicant]
Sun, “Structural Recognition of Immunoglobulins by FcV Receptors,” Elsevier Science & Technology, Ch. 7:131-144, (2013).
[cited by applicant]
Tan et al., “Influence of the hinge region on complement activation, C1q binding, and segmental flexibility in chimeric human immunoglobulins,”, Proc. Natl. Acad. Sci. USA, 87:162-166, (1990).
[cited by applicant]
Teeling et al., “Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas,” Blood, 104:1793-1800, (2004).
[cited by applicant]
Thakur et al., “Activated T cells from umbilical cord blood armed with anti-CD3 x anti-CD20 bispecific antibody mediate specific cytotoxicity against CD20+ targets with minimal allogeneic reactivity: a strategy for prov…
[cited by applicant]
Thakur et al., “Cancer therapy with bispecific antibodies: Clinical experience,” NIH Public Access, Curr Opin Mol Ther., vol. 12(3): 340-349, (2010).
[cited by applicant]
Thomas et al., “Chemiommunotherapy with a modified hyper-CVAD and Rituximab Regiment improves outcome in De Novo Philadelphia Chromosome-Negative Precursor B-Lineage Acute Lymphoblastic Leukemia,” Journal of Clinical On…
[cited by applicant]
Topp et al., “Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leu,aemia: a multiventre, single-arm, phase 2 study,” The Lancet, vol. 16:57-66, (2015).
[cited by applicant]
Tsai et al., “Regulation of CD20 in Rituximab-Resistant Cell Lines and B-cell Non-Hodgkin Lymphoma,” Clinical Cancer Research, vol. 18(No. 4):1039-1050, (2012).
[cited by applicant]
U.S. Appl. No. 14/031,075, Final Office Action mailed Sep. 14, 2016.
[cited by applicant]
U.S. Appl. No. 14/031,075, Non-Final Office Action mailed Apr. 15, 2016.
[cited by applicant]
U.S. Appl. No. 14/031,075, Notice of Allowance mailed Jan. 18, 2014.
[cited by applicant]
U.S. Appl. No. 14/031,075, Requirement for Restriction/Election mailed Nov. 19, 2015.
[cited by applicant]
U.S. Appl. No. 14/170,166, Non-Final Office Action mailed Dec. 21, 2015.
[cited by applicant]
U.S. Appl. No. 14/170,166, Notice of Allowance mailed Apr. 11, 2016.
[cited by applicant]
U.S. Appl. No. 14/170,166, Requirement for Restriction/Election mailed Jul. 27, 2015.
[cited by applicant]
U.S. Appl. No. 14/661,334, Final Office Action mailed Jun. 27, 2019.
[cited by applicant]
U.S. Appl. No. 14/661,334, Non-Final Office Action mailed Dec. 18, 2018.
[cited by applicant]
U.S. Appl. No. 14/661,334, Notice of Allowance mailed Sep. 17, 2019.
[cited by applicant]
U.S. Appl. No. 14/661,334, Requirement for Restriction/Election mailed Mar. 6, 2017.
[cited by applicant]
U.S. Appl. No. 14/661,334, Requirement for Restriction/Election mailed Sep. 11, 2017.
[cited by applicant]
U.S. Appl. No. 15/147,791, Non-Final Office Action mailed Sep. 27, 2017.
[cited by applicant]
U.S. Appl. No. 15/147,791, Notice of Allowance mailed Mar. 1, 2018.
[cited by applicant]
U.S. Appl. No. 15/147,791, Notice of Allowance mailed Jun. 12, 2018.
[cited by applicant]
U.S. Appl. No. 15/386,443, Non-Final Office Action mailed Dec. 18, 2018.
[cited by applicant]
U.S. Appl. No. 15/386,443, Requirement for Restriction/Election mailed Apr. 20, 2018.
[cited by applicant]
U.S. Appl. No. 15/386,443, Requirement for Restriction/Election mailed Sep. 19, 2018.
[cited by applicant]
U.S. Appl. No. 15/489,666, Final Office Action mailed Sep. 10, 2020.
[cited by applicant]
U.S. Appl. No. 15/489,666, Non-Final Office Action mailed Feb. 11, 2020.
[cited by applicant]
U.S. Appl. No. 15/489,666, Notice of Allowance mailed Mar. 24, 2021.
[cited by applicant]
U.S. Appl. No. 15/489,666, Requirement for Restriction/Election mailed Jun. 18, 2019.
[cited by applicant]
U.S. Appl. No. 15/527,002, Non-Final Office Action mailed Mar. 8, 2019.
[cited by applicant]
U.S. Appl. No. 15/527,002, Notice of Allowance mailed Jan. 13, 2020.
[cited by applicant]
U.S. Appl. No. 15/527,002, Requirement for Restriction/Election mailed Aug. 24, 2018.
[cited by applicant]
U.S. Appl. No. 15/562,881, Notice of Allowance mailed Jun. 12, 2019.
[cited by applicant]
U.S. Appl. No. 15/562,881, Notice of Allowance mailed Sep. 25, 2019.
[cited by applicant]
U.S. Appl. No. 15/780,504, Non-Final Office Action mailed Oct. 20, 2020.
[cited by applicant]
U.S. Appl. No. 15/780,504, Requirement for Restriction/Election mailed Apr. 7, 2020.
[cited by applicant]
U.S. Appl. No. 15/934,447, Final Office Action mailed Dec. 4, 2020.
[cited by applicant]
U.S. Appl. No. 15/934,447, Non-Final Office Action mailed May 8, 2020.
[cited by applicant]
U.S. Appl. No. 15/934,447, Notice of Allowance mailed Jun. 24, 2021.
[cited by applicant]
U.S. Appl. No. 15/934,447, Requirement for Restriction/Election mailed Oct. 17, 2019.
[cited by applicant]
U.S. Appl. No. 16/128,907, Non-Final Office Action mailed Sep. 22, 2020.
[cited by applicant]
U.S. Appl. No. 16/556,885, Non-Final Office Action mailed Mar. 29, 2022.
[cited by applicant]
U.S. Appl. No. 16/556,885, Notice of Allowance mailed Oct. 26, 2022.
[cited by applicant]
U.S. Appl. No. 16/556,885, Requirement for Restriction/Election mailed Nov. 9, 2021.
[cited by applicant]
U.S. Appl. No. 16/716,980, Notice of Allowance mailed Apr. 28, 2022.
[cited by applicant]
U.S. Appl. No. 16/720,623, Non-Final Office Action mailed Feb. 14, 2022.
[cited by applicant]
U.S. Appl. No. 16/720,623, Notice of Allowance mailed Jul. 7, 2022.
[cited by applicant]
Vafa, et al., “An engineered Fc variant of an IgG eliminates all immune effector functions via structural perturbations”, 65:114-126, (2014). (published online Jul. 17, 2013).
[cited by applicant]
Van Meerten et al., “CD2O-Targeted Therapy: The Next Generation of Antibodies,” Semin Hematol, 47:199-210, (2010).
[cited by applicant]
Varghese et al., “A Novel CD20-CD3 Bispecific Fully Human Antibody Induces Potent Anti-Tumor Effects Against B Cell Lymphoma in Mice,” Blood, vol. 124 (21) 4501 (2014). [http://doi.org/10.1182/blood.V124.21.4501.4501].
[cited by applicant]
Venclexta (venetoclax) tablets, for oral use Initial U.S. Approval: 2016; “Highlights of Prescribing Information.,” package insert.
[cited by applicant]
Vidarsson et al., “IgG Subclasses and Allotypes: From Structure to Effector Functions,” Frontiers in Immunology, vol. 5, Article 520,18 pages, doi: 10.3389/fimmu.2014.00520, (2014).
[cited by applicant]
Wang et al., “Treatment of CD33-directed Chimeric Antigen Receptor-modified T Cells in One Patient With Relapsed and Refractory Acute Myeloid Leukemia,” The American Society of Gene & Cell Therapy, vol. 23 (No. 1), 184-…
[cited by applicant]
Ward et al., “The effector functions of immunoglobulins: implications for therapy,” Therapeutic Immunology, 2:77-94, (1995).
[cited by applicant]
Wark et al., “Latest technologies for the enhancement of antibody affinity”, Advanced Drug Delivery Reviews, 58(5-6):657-670, (2006).
[cited by applicant]
Weinglass et al., “Engineering Conformational Flexibility in the Lactose Permease of
[cited by applicant]
Winkler et al., “Changing the Antigen Binding Specificity by Single Point Mutations of an Anti-p24 (HIV-1) Antibody,” J. Immunol., 165:4505-4514, (2000).
[cited by applicant]
WIPO Application No. PCT/US2013/060511, PCT International Search Report and Written Opinion of the International Searching Authority mailed Feb. 20, 2014.
[cited by applicant]
WIPO Application No. PCT/US2014/014175, PCT International Preliminary Report on Patentability mailed Aug. 13, 2015.
[cited by applicant]
WIPO Application No. PCT/US2014/014175, PCT International Search Report and Written Opinion of the International Searching Authority mailed Jul. 9, 2014.
[cited by applicant]
WIPO Application No. PCT/US2015/021322, PCT International Search Report and Written Opinion of the International Searching Authority mailed Jul. 2, 2015.
[cited by applicant]
WIPO Application No. PCT/US2015/061139, PCT International Search Report and Written Opinion of the International Searching Authority mailed Feb. 18, 2016.
[cited by applicant]
WIPO Application No. PCT/US2016/025051, PCT International Search Report and Written Opinion of the International Searching Authority mailed Oct. 12, 2016.
[cited by applicant]
WIPO Application No. PCT/US2016/053525, PCT International Search Report and Written Opinion of the International Searching Authority mailed Mar. 8, 2017.
[cited by applicant]
WIPO Application No. PCT/US2016/068003, PCT International Search Report mailed Mar. 31, 2017.
[cited by applicant]
WIPO Application No. PCT/US2016/068003, PCT Written Opinion of the International Searching Authority mailed Mar. 31, 2017.
[cited by applicant]
WIPO Application No. PCT/US2019/049027, PCT International Search Report and Written Opinion of the International Searching Authority mailed Nov. 28, 2019.
[cited by applicant]
Wolach et al., “Blinatumomab for the Treatment of Philadelphia Chromosome-Negative, Precursor B-cell Acute Lymphoblastic Leukemia,” Clinical Cancer Research, vol. 21 (No. 19):4262-4269, (2015).
[cited by applicant]
Wu et al., “Fab-based bispecific antibody formats with robust biophysical properties and biological activity,” MABS, pp. 470-482, ISSN: 1942-0870, (2015).
[cited by applicant]
Wypych et al., “Human IgG2 Antibodies Display Disulfide-mediated Structural Isoforms,” Journal of Biological Chemistry, 283(23):16194-16205, (2008).
[cited by applicant]
Xiong et al., “Efficient inhibition of human B-cell lymphoma xenografts with an anti-CD20 X anti-CD3 bispecific diabody”, Cancer Letters, 177:29-39, (2002).
[cited by applicant]
Xu et al., “Residue at Position 331 in the Igg1 and Igg4 Ch2 Domains Contributes to Their Differential Ability to Blind and Activate Complement,” Journal of Biological Chemistry, 269(5):3469-3474, (1994).
[cited by applicant]
Yuen et al., “B lymphocytes and cancer: a love-hate relationship,” Trends Cancer Dec. 2016; 2(12): 747-757.
[cited by applicant]
Akbar et al., “A compact vocabulary of paratope-epitope interactions enables predictability of antibody-antigen binding,” Cell Reports Article, vol. 34:1-15, (2021).
[cited by applicant]
Bannerji et al., “Emerging Clinical Activity of REGN1979, an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Follicular Lymphoma (FL), Diffuse Large B-Cell Lymphoma (DLBCL), and Other B-Ce…
[cited by applicant]
Bannerji et al., “Safety and Preliminary Clinical Activity of REGN1979, an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Patients with BNHL Previously Treated with CD20-Directed Antibody Therapy,” Blood blood, vol. 130 (…
[cited by applicant]